Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Ovarian Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Lymphoma 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rhabdomyosarcoma, Alveolar 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Mesothelioma, Malignant 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1Ataxia Telangiectasia 1

Interventions

Cisplatin 30Magnetic Resonance Spectroscopy 21Radiotherapy 20pembrolizumab 18Specimen Handling 17Cetuximab 16Radiotherapy, Intensity-Modulated 11Paclitaxel 11Carboplatin 11Fluorouracil 10Biopsy 101,2-diaminocyclohexaneplatinum II citrate 10Radiation 9Platinum 9Drug Therapy 9Taxes 7Surgical Procedures, Operative 7Celecoxib 7X-Rays 6Standard of Care 6Sentinel Lymph Node Biopsy 6Surveys and Questionnaires 5Nivolumab 5cemiplimab 4Metformin 4Fluorodeoxyglucose F18 4Docetaxel 4Chemoradiotherapy 4(225)Ac-DOTA-c(RGDyK) 4durvalumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mouth Neoplasms × BAY 1895344 × Clear all
NCT04576091 2024-12-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
7 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡